ROCHE HLDG DR (RHO5 HM) stock market data APIs
€275.2601
2.88(1%)
as of July 18, 2025
Try our APIs with
free plan!
ROCHE HLDG DR Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for RHO5.HM.
Prev. Close
275.2601
Open
278.1445
High
278.1445
Low
273.5371
52 wk Range
235.4067-293.3
Market Cap
312 681 M
Dividends (Yield)
0.0415
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ROCHE HLDG DR data using free add-ons & libraries
Get ROCHE HLDG DR Fundamental Data
ROCHE HLDG DR Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ROCHE HLDG DR News
New
Genentech Provides Update on Supplemental Biologics License Application for Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
SOUTH SAN FRANCISCO, Calif., July 18, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) issue...
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?
Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock has underperformed the medical sector and S&P 500 Index in this timeframe...
Favorable Government Support Fuels Germany's Biotech Innovation and Commercialization: Market to Surpass USD 94 Billion by 2034 Led by QIAGEN, Thermo Fisher Scientific, Illumina and Roche
Company Logo German Biotechnology MarketGerman Biotechnology Market Dublin, July 18, 2025 (GLOBE NEWSWIRE) -- The "Germany Biotechnology Market Report and Forecast 2025-2034" has been added to Rese...
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock
Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the acquisition of Rallybio’s full stake in their joint venture earlier this ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
